SCHEMBL24536232

SCHEMBL24536232

COc1cc(Br)c(Cl)c(OC)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
PRKDC P78527 1/20 0.36
TUBB1 Q9H4B7 4/20 0.36
TUBB4A P04350 2/20 0.36
TUBB P07437 2/20 0.36
TUBA3C P0DPH7 2/20 0.36
TUBA1B P68363 2/20 0.36
TUBA4A P68366 2/20 0.36
TUBB4B P68371 2/20 0.36
TUBB3 Q13509 2/20 0.36
TUBB2A Q13885 2/20 0.36
TUBB8 Q3ZCM7 2/20 0.36
TUBA3E Q6PEY2 2/20 0.36
TUBA1A Q71U36 2/20 0.36
TUBA1C Q9BQE3 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9549445 0.82 CA2 (0.38) CA2CA4TUBB1PTGS2
SCHEMBL5704414 0.76 CA2 (0.39) CA2CA4TUBB1TSHRAPOBEC3A
SCHEMBL27988498 0.74 ACHE (0.46) MAPTTUBB1TUBB4ATUBBTUBA3C
SCHEMBL9678358 0.73 POLB (0.46) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL1729022 0.72 MAPT (0.48) POLBL3MBTL1MAPTNPSR1CA2
SCHEMBL24572813 0.72 MAPT (0.48) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL9804695 0.71 CA2 (0.42) POLBL3MBTL1MAPTNPSR1CA2
SCHEMBL6078582 0.71 NPSR1 (0.34) POLBL3MBTL1MAPTNPSR1TUBB1
SCHEMBL1094358 0.70 POLB (0.37) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL624239 0.69 ALOX5AP (0.46) MAPTTUBB1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-25 US disclosed
US-12398154-B2 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. (US) 2025-08-26 US disclosed
CN-116829151-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2023-09-29 CN disclosed
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. 2023-03-09 US disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS POLB 1429/4885L3MBTL1 3327/4885MAPT 4490/4885
US-12398154-B2 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS POLB 1429/4885L3MBTL1 3327/4885MAPT 4490/4885
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS POLB 1331/4885L3MBTL1 1272/4885MAPT 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.